Valuation: Femasys Inc.

Market Cap 9.38M 8.52M 7.87M 7.1M 13.4M 876M 13.91M 94.78M 37.49M 473M 35.19M 34.45M 1.49B P/E 2026 *
-0.46x
P/E 2027 * -0.54x
Enterprise Value 9.38M 8.52M 7.87M 7.1M 13.4M 876M 13.91M 94.78M 37.49M 473M 35.19M 34.45M 1.49B EV / Sales 2026 *
5.98x
EV / Sales 2027 * 1.52x
Free-Float
92.8%
Yield 2026 *
-
Yield 2027 * -
14/11 Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
03/11 Femasys Inc. Announces Resignation of Kenneth D. Eichenbaum as Director, Effective on October 30, 2026 CI
31/10 Femasys Inc. Announces Appointment of John Moorhead to Board of Directors as A Board Designee CI
21/10 Femasys Inc. Partners With SandsRx Pharmacy To Support FemaSeed Fertility Portfolio Launch To OB/GYNs CI
15/10 Femasys Inc. Doubles Actively Enrolling Sites In Its FemBloc FINALE Pivotal Trial Across The United States CI
16/09 Femasys Inc. And Minnesota Women?s Care Implement FemaSeed Fertility Portfolio Across All Four Locations CI
10/09 Femasys Inc. Partners With CapexMD To Expand Patient Access To FemaSeed Fertility Portfolio CI
26/08 Femasys Partners With UNC Health To Introduce FemaSeed Fertility Portfolio Across Statewide OB/GYN Care Locations CI
19/08 Femasys Announces FDA Approval Of Modular PMA Submission Approach For FemBloc CI
15/08 Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
12/08 Femasys Inc. Expands Global Patent Protection for Fembloc with Issuance of Blended Polymer Patents CI
10/08 Femasys Inc. announced that it has received $29.999561 million in funding from Rosalind Advisors, Inc., Nantahala Capital Management, LLC and other investors. CI
07/08 Femasys Inc. announced that it expects to receive $29.999561 million in funding from Rosalind Advisors, Inc., Nantahala Capital Management, LLC and other investors. CI
1 day-2.23%
1 week-27.00%
Current month-20.07%
1 month-32.82%
3 months-50.23%
6 months-84.91%
Current year-90.50%
1 week 1.07
Extreme 1.07
1.55
1 month 1.07
Extreme 1.07
1.77
Current year 1.07
Extreme 1.07
14.51
1 year 1.07
Extreme 1.07
20.8
3 years 1.07
Extreme 1.07
48
5 years 1.07
Extreme 1.07
118.8
10 years 1.07
Extreme 1.07
275
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2004
Director of Finance/CFO 58 28/02/2022
Chief Operating Officer 52 30/03/2026
Director TitleAgeSince
Chairman 58 01/01/2004
Chairman 74 06/07/2022
Director/Board Member 75 01/08/2005
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Buy

Chief Technology Officer

9,375 0.1166%
7/8/26 Buy

Chief Financial Officer

46,875 0.5832%
7/8/26 Buy

Founder

46,875 0.5832%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-27.00%-92.40%-94.24% 9.38M
-0.43%-4.95%-20.10%+2.64% 181B
-2.02%-1.86%-1.07%+32.68% 125B
-0.51%-0.74%-11.98%+9.39% 121B
+1.26%-0.82%-41.86%+2.53% 90.52B
-1.08%-1.02%-4.24%+76.75% 66.9B
-0.29%+0.42%+12.01%-7.81% 58.68B
+0.13%-0.89%+3.90%+47.25% 54.38B
+0.86%-0.15%-1.84%+38.65% 48.46B
+0.83%+4.64%+3.84%-1.21% 35.4B
Average -0.32%-1.51%-15.37%+10.66% 78B
Weighted average by Cap. -0.34%-1.52%-10.66%+19.20%

Financials

2026 *2027 *
Net sales 1.57M 1.42M 1.31M 1.19M 2.24M 147M 2.33M 15.84M 6.27M 79.05M 5.88M 5.76M 250M 6.19M 5.62M 5.19M 4.68M 8.84M 578M 9.18M 62.52M 24.73M 312M 23.21M 22.73M 986M
Net income -16.34M -14.83M -13.7M -12.36M -23.34M -1.53B -24.23M -165M -65.31M -824M -61.31M -60.02M -2.6B -22.23M -20.18M -18.64M -16.82M -31.75M -2.08B -32.97M -225M -88.86M -1.12B -83.41M -81.66M -3.54B
Net Debt - -
Projected Income Statement - Annual - Femasys Inc.
Logo Femasys Inc.
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Employees
53
Date Price Change Volume
19/11/26 USD 1.090 -2.68% 27,504
17/11/26 USD 1.120 -12.50% 110,562
16/11/26 USD 1.280 -9.86% 131,870
13/11/26 USD 1.420 +1.43% 52,889
12/11/26 USD 1.400 -6.67% 88,213
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Femasys Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.120USD
Average target price
14.75USD
Spread / Average Target
+1,216.96%
  1. Stock Market
  2. Stocks
  3. FEMY Stock